Chemo-Induced Nausea
Find information on chemo-induced nausea (CINV), also known as chemotherapy-induced nausea and vomiting. This resource offers guidance for healthcare professionals on clinical documentation and medical coding related to CINV. Learn about managing chemotherapy-induced nausea and vomiting, including diagnosis codes and best practices for patient care. Explore resources for CINV, including support for healthcare providers and patients experiencing this chemotherapy side effect.
Nausea and vomiting caused by chemotherapy drugs.
Nausea, vomiting, retching, aversion to food, dehydration.
Oncology clinics, hospitals, outpatient infusion centers.
ICD-10 Code Families
Complete code families applicable to T45.1X5A
When to use each related code
| Description | When to use |
|---|---|
| Nausea caused by chemotherapy | Use for nausea temporally related to chemotherapy. Consider CINV subtypes. |
| Nausea and vomiting caused by chemotherapy | Use for nausea AND vomiting temporally related to chemotherapy. Specify CINV subtype if known. |
| Anticipatory nausea related to chemotherapy | Use for nausea/vomiting BEFORE chemotherapy due to learned response. |
Best-practice checklist
- ✓Chemotherapy induced nausea (CINV) diagnosis documented
- ✓Severity of CINV (mild, moderate, severe) specified
- ✓Document antiemetic medications prescribed and response
- ✓Nausea onset, frequency, duration, and associated symptoms
- ✓Impact of CINV on patient's nutritional status and QOL
Common pitfalls to avoid
Coding CINV without specifying if it's acute, delayed, or anticipatory can lead to inaccurate reimbursement and quality reporting.
Failing to document and code CINV can underestimate the severity of chemotherapy side effects, impacting patient care and resource allocation.
Incorrectly coding the severity of CINV (mild, moderate, severe) affects reimbursement and clinical trial eligibility.
Best-practice tips
- 01Prophylactic antiemetics prior to chemotherapy
- 02Combinational antiemetic therapy for high-risk CINV
- 03Patient education on dietary adjustments, hydration
- 04Assess and document nausea severity regularly (VAS)
- 05Consider non-pharmacological interventions: acupuncture, relaxation
Step-by-step checklist
- 1
Verify patient received chemotherapy within past 5 days.
- 2
Assess nausea timing and severity (acute, delayed, anticipatory).
- 3
Document symptoms and impact on patient's daily activities.
- 4
Review antiemetic prophylaxis and rescue medications prescribed.
- 5
Consider differential diagnoses if symptoms atypical for CINV.
Ready-to-paste narrative
Patient presents with complaints consistent with chemotherapy-induced nausea and vomiting (CINV). Onset of nausea correlated with recent chemotherapy administration for [Document specific chemotherapy regimen, e.g., FOLFOX regimen for colon cancer]. Patient reports [Describe nausea severity, e.g., mild, moderate, severe] nausea characterized by [Describe nausea characteristics, e.g., a constant queasiness, episodic waves of nausea]. The patient also reports [Document presence and characteristics of vomiting, e.g., no vomiting, two episodes of emesis containing undigested food]. Patient's current antiemetic regimen includes [List current antiemetic medications, dosages, and routes of administration]. Assessment reveals [Document pertinent physical exam findings related to hydration status and abdominal exam, e.g., dry mucous membranes, mild epigastric tenderness on palpation, normal bowel sounds]. Differential diagnosis includes other causes of nausea and vomiting such as medication side effects, infection, and bowel obstruction. Given the temporal relationship to chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is the most likely diagnosis. Plan includes [Outline plan for managing CINV, e.g., adjustment of antiemetic regimen to include a 5-HT3 receptor antagonist and a corticosteroid, patient education on dietary modifications, monitoring for dehydration, and follow-up]. Patient advised to contact the clinic if symptoms worsen or do not improve with the adjusted treatment plan. ICD-10 code R11.2 (nausea and vomiting) and CPT code 99214 (established patient office visit, level 4) are considered appropriate for this encounter based on the complexity of medical decision making. This documentation supports medical necessity for antiemetic therapy.
Common questions and answers
What are the most effective antiemetic guidelines for managing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy?+
Current antiemetic guidelines, such as those from the National Comprehensive Cancer Network (NCCN), recommend a combination of antiemetics for highly emetogenic chemotherapy (HEC). This typically includes a 5-HT3 receptor antagonist, a neurokinin-1 receptor antagonist, and a corticosteroid like dexamethasone. For some patients, the addition of olanzapine may be considered. The specific regimen should be tailored to the individual patient's risk factors, including age, comorbidities, and previous CINV experience. Explore how implementing these guideline-based approaches can improve patient outcomes and reduce CINV-related complications. Consider consulting the latest NCCN guidelines for detailed recommendations and specific chemotherapy regimens.
How can I differentiate between anticipatory nausea and vomiting versus acute or delayed CINV in my chemotherapy patients, and what are the best management strategies for each?+
Anticipatory nausea and vomiting (ANV) typically occurs before chemotherapy administration and is often triggered by previous negative experiences. It's distinct from acute CINV, which develops within 24 hours of chemotherapy, and delayed CINV, which occurs more than 24 hours after treatment. Managing ANV involves behavioral therapies like relaxation techniques and guided imagery, as well as prophylactic antiemetics. Acute and delayed CINV are managed with different combinations of antiemetics depending on the emetogenicity of the chemotherapy regimen. For acute CINV, 5-HT3 receptor antagonists are key, while delayed CINV often benefits from neurokinin-1 receptor antagonists. Learn more about effective strategies for differentiating and managing these various types of CINV to provide personalized patient care.
Beyond standard antiemetic medications, what complementary and integrative therapies are evidence-based for managing breakthrough chemotherapy-induced nausea and vomiting in my oncology patients?+
Several complementary and integrative therapies have shown promise in managing breakthrough CINV when standard antiemetics are insufficient. Acupuncture, acupressure, and ginger supplementation have demonstrated some efficacy in reducing nausea symptoms. Mind-body techniques like relaxation, meditation, and hypnosis can also be helpful for some patients. It's important to note that these therapies should be used as adjuncts to, not replacements for, conventional antiemetic medications. Consider implementing these evidence-based integrative approaches in a multidisciplinary setting to provide comprehensive CINV management for your patients. Explore the latest research on integrative oncology for more insights.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.